Table of contents:
Ministry of Defense: Russian vaccine against COVID-19 has formed an immune response in volunteers
The Ministry of Defense together with the Center for Epidemiology and Microbiology named after N.F. The Gamalei have announced the final stage of clinical trials of a coronavirus vaccine.
Photo: CC0 Public Domain
Clinical trials of the Russian drug began on June 18 at the Burdenko military hospital and the Sechenov University with the participation of two groups of volunteers of 38 people each. A vaccine developed by scientists at the Center for Epidemiology and Microbiology. N.F. Gamalea, has two forms - in the form of liquid and powder for solution preparation. Both forms are intended for intramuscular administration.
Analyzes of volunteers from both groups showed that they had formed an immune response to coronavirus infection - this is a key indicator of the effectiveness of the vaccine, RBC reports, citing a message from the Ministry of Defense. On July 15, volunteers from the first group, with the help of which the tolerance and safety of the drug were tested, will be discharged from the hospital.
On July 13, study participants in the second group will receive a second dose of the vaccine. The first injection was to test the effectiveness and immunogenicity of the drug, the second was to strengthen the immune system and increase its duration.
The Ministry of Defense reports that all participants feel good, their psychological and moral state is also normal. No side effects of the vaccine have been identified. On the 42nd day after vaccination, the volunteers will have to return to the hospital for a final medical examination and registration of the necessary documentation.
In the register of clinical trials (RCT) of the Ministry of Health, the completion of the drug trials is scheduled for December 31, 2020.